Urine gamma-synuclein as a biomarker for the diagnosis of bladder cancer (Q37536597)

20 August 2017

Urine gamma-synuclein as a biomarker for the diagnosis of bladder cancer (English)

1 reference

20 August 2017

0 references

1 reference

Caiyun Liu

1 reference

20 August 2017

Bingbing Shi

1 reference

20 August 2017

Chonghua Hao

1 reference

20 August 2017

Qinghai Wang

1 reference

20 August 2017

Qiang Lv

1 reference

20 August 2017

Nianzeng Xing

1 reference

20 August 2017

Jianzhong Shou

1 reference

20 August 2017

Like Qu

1 reference

20 August 2017

Yanning Gao

1 reference

20 August 2017

Chao Qin

1 reference

20 August 2017

Jiyu Zhao

1 reference

20 August 2017

Chengchao Shou

1 reference

20 August 2017

language of work or name

English

0 references

publication date

19 May 2016

1 reference

20 August 2017

1 reference

20 August 2017

1 reference

20 August 2017

1 reference

20 August 2017

43432-43441

1 reference

Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5190035

Unconventional secretion of synuclein-γ promotes tumor cell invasion

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5190035

Influencing factors on the NMP-22 urine assay: an experimental model

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5190035

Role of gamma-synuclein in microtubule regulation

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5190035

The reciprocal regulation of gamma-synuclein and IGF-I receptor expression creates a circuit that modulates IGF-I signaling.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5190035

Synuclein gamma predicts poor clinical outcome in colon cancer with normal levels of carcinoembryonic antigen

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5190035

Synuclein gamma stimulates membrane-initiated estrogen signaling by chaperoning estrogen receptor (ER)-alpha36, a variant of ER-alpha.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5190035

Proteomic assays for the detection of urothelial cancer

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5190035

Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5190035

Economic aspects of bladder cancer: what are the benefits and costs?

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5190035

Gamma-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5190035

Urine based markers of urological malignancy

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5190035

Urine cytology. It is still the gold standard for screening?

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5190035

Synuclein γ protects Akt and mTOR and renders tumor resistance to Hsp90 disruption

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5190035

Urine markers for detection and surveillance of bladder cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5190035

ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5190035

Epidemiology and risk factors of urothelial bladder cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5190035

Synuclein-gamma is closely involved in perineural invasion and distant metastasis in mouse models and is a novel prognostic factor in pancreatic cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5190035

Applications of novel monoclonal antibodies specific for synuclein-gamma in evaluating its levels in sera and cancer tissues from colorectal cancer patients

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5190035

Overexpression of synuclein-gamma in pancreatic adenocarcinoma

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5190035

Neuronal protein synuclein gamma predicts poor clinical outcome in breast cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5190035

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials

25 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5190035

Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, gamma -synuclein, and catechol-o-methyltransferase) identified by proteomic analysis

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5190035

Urinary tract infection and patient satisfaction after flexible cystoscopy and urodynamic evaluation

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5190035

Panel of Urinary Diagnostic Markers for Non-Invasive Detection of Primary and Recurrent Urothelial Urinary Bladder Carcinoma

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5190035

Elevated serum synuclein-gamma in patients with gastrointestinal and esophageal carcinomas

3 December 2018

1 reference

12 December 2020

Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis

1 reference

12 December 2020

False-positive results of the NMP22 test due to hematuria

1 reference

12 December 2020

The BTA stat test is nonspecific for hematuria: an experimental hematuria model

1 reference

12 December 2020

Combined phenotype of 4 markers improves prognostic value of patients with colon cancer

1 reference

12 December 2020

Urinary bladder cancer test: a new urinary tumor marker in the follow-up of superficial bladder cancer

1 reference

12 December 2020

Identifiers

DOI

10.18632/ONCOTARGET.9468

1 reference

20 August 2017

1 reference

20 August 2017

PubMed publication ID

27223068

1 reference